Elotuzumab

Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma. The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody.'-mexi-' (melanoma): Ecromeximab§ Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma. The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody. In May 2014, it was granted 'Breakthrough Therapy' designation by the FDA (for multiple myeloma). On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications. Elotuzumab was labeled for use with lenalidomide and dexamethasone. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. In May 2016 the EC/EU gave a similar approval.